Redmile Group, LLC Fate Therapeutics Inc Transaction History
Redmile Group, LLC
- $1.53 Billion
- Q2 2024
A detailed history of Redmile Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 13,169,057 shares of FATE stock, worth $44.6 Million. This represents 2.82% of its overall portfolio holdings.
Number of Shares
13,169,057
Previous 13,169,057
-0.0%
Holding current value
$44.6 Million
Previous $96.7 Million
55.31%
% of portfolio
2.82%
Previous 3.81%
Shares
12 transactions
Others Institutions Holding FATE
# of Institutions
190Shares Held
123MCall Options Held
15KPut Options Held
14K-
Vanguard Group Inc Valley Forge, PA10.6MShares$35.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$34.3 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA8.22MShares$27.9 Million1.5% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$18.9 Million0.6% of portfolio
-
State Street Corp Boston, MA5.34MShares$18.1 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $329M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...